Advertisement

Sepsis Trials in Children

  • G. Zobel
Conference paper

Abstract

Sepsis remains an important cause of morbidity and mortality in children, despite the availability of antibiotic therapy, specialized transport of critically ill children, and advances in paediatric intensive care [1]. Though mortality from paediatric sepsis has declined substantially from the pre-antibiotic era, reported mortality remains high, ranging from 10 to 40% [2–4].

Keywords

Septic Shock Bacterial Meningitis Meningococcal Disease Systemic Vascular Resistance Index Purpura Fulminans 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Pollard AJ, Britto J, Nadel S et al (1999) Emergency management of meningococcal disease. Arch Dis Child 80: 290–296PubMedCrossRefGoogle Scholar
  2. 2.
    Jafari HS, McCracken GH (1992) Sepsis and septic shock: a review for clinicians. Pediatr Infect Dis J 11: 739–748PubMedCrossRefGoogle Scholar
  3. 3.
    Anderson MR, Blumer JL (1997) Advances in the therapy for sepsis in children. Pediatr Clin North Am 44: 179–205PubMedCrossRefGoogle Scholar
  4. 4.
    Butt W (2001) Septic shock. Pediatr Clin North Am 48: 601–625CrossRefGoogle Scholar
  5. 5.
    De Kleijn ED, Hazelzet JA, Kornelisse RF et al (1998) Pathophysiology of meningococcal sepsis in children. Eur J Pediatr 157: 869–880PubMedCrossRefGoogle Scholar
  6. 6.
    American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference Committee (1992) Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 20: 864–874CrossRefGoogle Scholar
  7. 7.
    Hayden WR (1994) Sepsis terminology in pediatrics. J Pediatr 124: 657–658PubMedGoogle Scholar
  8. 8.
    Schibler KR, Osborne KA, Leung LY et al (1998) A randomized, placebo-controlled trial of granulocyte colony-stimulating factor administration to newborn infants with neutropenia and clinical signs of early-onset sepsis. Pediatrics 102: 6–13PubMedCrossRefGoogle Scholar
  9. 9.
    Garcia-Cabonero R, Mayordomo JI, Tornamira MV et al (2001) Granulocyte colony-stimulating factor in the treatment of high-risk febrile neutropenia: a multicenter randomized trial. J Natl Cancer Inst 93: 31–38CrossRefGoogle Scholar
  10. 10.
    Parker MM (1998) Pathophysiology of cardiovascular dysfunction in septic shock. New Horizons 6: 130–138PubMedGoogle Scholar
  11. 11.
    Carcillo JA, Davis AL, Zaritsky A (1991) Role of early fluid resuscitation in pediatric septic shock. JAMA 266: 1242–1245PubMedCrossRefGoogle Scholar
  12. 12.
    Ceneviva G, Paschall A, Maffei F et al (1998) Hemodynamic support in fluid-refractory pediatric septic shock. Pediatrics 102: e19Google Scholar
  13. 13.
    Barton P, Garcia J, Kouatli A et al (1996) Hemodynamic effects of i.v. milrinone lactate in pediatric patients with septic shock. A prospective, double-blinded, randomized, placebo-controlled, intervention study. Chest 109: 1302–1312PubMedCrossRefGoogle Scholar
  14. 14.
    Hatherill M, Tibby SM, Turner Ch et al (2000) Procalcitonin and cytokine levels: Relationship to organ failure and mortality in pediatric septic shock. Crit Care Med 28: 2591–2594PubMedCrossRefGoogle Scholar
  15. 15.
    Doughty LA, Kaplan SS, Carcillo JA (1996) Inflammatory cytokine and nitric oxide responses in pediatric sepsis and organ failure. Crit Care Med 24: 1137–1143PubMedCrossRefGoogle Scholar
  16. 16.
    Doughty LA, Kaplan SS, Carcillo JA (1998) Plasma nitrite and nitrate concentrations in pediatric sepsis. Crit Care Med 26: 157–162PubMedCrossRefGoogle Scholar
  17. 17.
    Carcillo JA (1999) Nitric oxide production in neonatal and pediatric sepsis. Crit Care Med 27: 1063–1065PubMedCrossRefGoogle Scholar
  18. 18.
    Riordan FA, Bestwick K, Thomson APJ et al (1999) Plasma fibronectin levels in meningococcal disease. Eur J Pediatr 158: 81–82CrossRefGoogle Scholar
  19. 19.
    Baines PB, Marzouk O, Thomson APJ et al (1999) Endothelial cell adhesion molecules in meningococcal disease. Arch Dis Child 80: 74–76PubMedCrossRefGoogle Scholar
  20. 20.
    Brandtzaeg P, Sandset PM, Joo GB et al (1989) The quantitative association of plasma endotoxin, antithrombin, protein C, extrinsic pathway inhibitor and fibropeptide A in systemic meningococcal disease. Thromb Res 55: 459–470PubMedCrossRefGoogle Scholar
  21. 21.
    Kornelisse RF, Hazelzet JA, Savelkoul HFJ et al (1996) The relationship between plasminogen activator inhibitor-1 and proinflammatory and counterinflammatory mediators in children with meningococcal septic shock. J Infect Dis 173: 1148–1156PubMedCrossRefGoogle Scholar
  22. 22.
    Bone RC, Fisher CJ, Clemmer TP et al (1987) A controlled trial of high-dose methylprednisolone in the treatment of severe sepsis and septic shock. N Engl J Med 317: 653–658PubMedCrossRefGoogle Scholar
  23. 23.
    Hinshwa L, Peduzzi P, Young E et al (1987) Effect of high-dose glucocorticoid therapy on mortality in patients with clinical signs of systemic sepsis. N Engl J Med 317: 659–665CrossRefGoogle Scholar
  24. 24.
    Odio CM, Faingezicht I, Paris M et al (1991) The beneficial effects of early dexamethasone administration in infants and children with bacterial meningitis. N Engl J Med 324: 1525–1531PubMedCrossRefGoogle Scholar
  25. 25.
    Mustafa MM, Ramilo O, Saez-Lorens X et al (1990) Cerebrospinal fluid prostaglandins, interleukin 1-beta, and tumor necrosis factor in bacterial meningitis. Am J Dis Child 144: 883–887PubMedGoogle Scholar
  26. 26.
    Slusher T, Gbadero D, Howard C et al (1996) Randomized, placebo-controlled, double blinded trial of dexamethasone in African children with sepsis. Pediatr Infect Dis J 15: 579–583PubMedCrossRefGoogle Scholar
  27. 27.
    J5 Study Group (1992) Treatment of severe infectious purpura in children with a human plasma from donors immunized with Escherichia coli J5: a prospective double-blind study. J Infect Dis 165: 695–701CrossRefGoogle Scholar
  28. 28.
    Derx B, Wittes J, McCloskey R, and the European Pediatric Meningococcal Septic Shock Trial Study Group (1999) Randomized, placebo-controlled trial of HA-1A, a human monoclonal antibody to endotoxin, in children with meningococcal septic shock. Clin Infect Dis 28: 770–777CrossRefGoogle Scholar
  29. 29.
    Levin M, Quint PA, Goldstein B et al (2000) Recombinant bactericidal/permeability-increasing protein (rBPI21) as adjunctive treatment for children with severe meningococcal sepsis: a randomized trial. Lancet 356: 961–967PubMedCrossRefGoogle Scholar
  30. 30.
    Thomson APJ, Sills JA, Hart CA (1991) Validation of the Glasgow Meningococcal Septicemia Prognostic Score: a year retrospective survey. Crit Care Med 19: 26–30PubMedCrossRefGoogle Scholar
  31. 31.
    Zenz W, Muntean W, Gallistl S et al (1995) Recombinant tissue plasminogen activator treatment in two infants with fulminant meningococcemia. Pediatrics 96: 144–148PubMedGoogle Scholar
  32. 32.
    White B, Livingstoone W, Murphy C et al (2000) An open-label study of the role of adjuvant hemostatic support with protein C replacement therapy in purpura fulminans-associated meningococcemia. Blood 96: 3719–3724PubMedGoogle Scholar
  33. 33.
    Reeves JH, Butt WW, Shann F et al (1999) Continuous plasmafiltration in sepsis syndrome. Plasmafiltration in Sepsis Study Group. Crit Care Med 27: 2096–2104PubMedCrossRefGoogle Scholar
  34. 34.
    Goldman AP, Kerr SJ, Butt W et al (1997) Extracorporeal support for intractable cardiorespiratory failure due to meningococcal disease. Lancet 349: 466–469PubMedCrossRefGoogle Scholar
  35. 35.
    Meyer DM, Jesson ME, and the Extracorporeal Life Support Organization (1997) Results of extracorporeal membrane oxygenation in children with sepsis. Ann Thorac Surg 63: 756–761PubMedCrossRefGoogle Scholar
  36. 36.
    Hermans PWM, Hibberd ML, Booy R et al (1999) 4G/5G promotor polymorphism in the plasminogen-activator-inhibitor-1 gene and outcome of meningococcal disease. Lancet 354:556–560PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Italia, Milano 2002

Authors and Affiliations

  • G. Zobel

There are no affiliations available

Personalised recommendations